Ranch Capital Advisors Inc. grew its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 10,547 shares of the company’s stock after acquiring an additional 85 shares during the period. Johnson & Johnson comprises 1.5% of Ranch Capital Advisors Inc.’s investment portfolio, making the stock its 17th biggest holding. Ranch Capital Advisors Inc.’s holdings in Johnson & Johnson were worth $1,863,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Glassy Mountain Advisors Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $35,000. Retirement Financial Solutions LLC acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $40,000. TD Capital Management LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $48,000. VitalStone Financial LLC acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $52,000. Finally, Iron Horse Wealth Management LLC grew its holdings in Johnson & Johnson by 112.8% during the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after acquiring an additional 159 shares in the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.20% of the stock is owned by corporate insiders.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same quarter in the prior year, the company posted $2.67 earnings per share. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.08%. The ex-dividend date is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is presently 99.58%.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on JNJ shares. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. Raymond James reduced their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. Finally, UBS Group initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $173.00.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.